<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>J Oger | Ehsan&#39;s Page</title>
    <link>/authors/J-Oger/</link>
      <atom:link href="/authors/J-Oger/index.xml" rel="self" type="application/rss+xml" />
    <description>J Oger</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Fri, 01 Jan 2016 00:00:00 +0000</lastBuildDate>
    <image>
      <url>img/map[gravatar:%!s(bool=false) shape:circle]</url>
      <title>J Oger</title>
      <link>/authors/J-Oger/</link>
    </image>
    
    <item>
      <title>Interferon beta and long-term disability in multiple sclerosis</title>
      <link>/publication/journal-article/2016-01-01_shirani2016interferon/</link>
      <pubDate>Fri, 01 Jan 2016 00:00:00 +0000</pubDate>
      <guid>/publication/journal-article/2016-01-01_shirani2016interferon/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs</title>
      <link>/publication/journal-article/2015-01-01_gibbs2015antibody/</link>
      <pubDate>Thu, 01 Jan 2015 00:00:00 +0000</pubDate>
      <guid>/publication/journal-article/2015-01-01_gibbs2015antibody/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Multiple sclerosis in older adults: the clinical profile and impact of interferon beta treatment</title>
      <link>/publication/journal-article/2015-01-01_shirani2015multiple/</link>
      <pubDate>Thu, 01 Jan 2015 00:00:00 +0000</pubDate>
      <guid>/publication/journal-article/2015-01-01_shirani2015multiple/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study</title>
      <link>/publication/journal-article/2014-01-01_shirani2014investigation/</link>
      <pubDate>Wed, 01 Jan 2014 00:00:00 +0000</pubDate>
      <guid>/publication/journal-article/2014-01-01_shirani2014investigation/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Marginal structural Cox models for estimating the association between beta-interferon exposure and disease progression in a multiple sclerosis cohort</title>
      <link>/publication/journal-article/2014-01-01_karim2014marginal/</link>
      <pubDate>Wed, 01 Jan 2014 00:00:00 +0000</pubDate>
      <guid>/publication/journal-article/2014-01-01_karim2014marginal/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Interferon beta and long-term disability in multiple sclerosis</title>
      <link>/publication/journal-article/2013-01-01_shirani2013interferon/</link>
      <pubDate>Tue, 01 Jan 2013 00:00:00 +0000</pubDate>
      <guid>/publication/journal-article/2013-01-01_shirani2013interferon/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis</title>
      <link>/publication/journal-article/2012-01-01_shirani2012association/</link>
      <pubDate>Sun, 01 Jan 2012 00:00:00 +0000</pubDate>
      <guid>/publication/journal-article/2012-01-01_shirani2012association/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
